RB 40/2015:Milestone Medical Inc. Presents Initial Results of Clinical Trials for its Epidural Instrument at Event for Leading Anesthesiologists and Key Opinion Leaders
Firma: MILESTONE MEDICALSpis treści:
1. RAPORT BIEŻĄCY
2. PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that it hosted an event on November 20th in Miami, FL (USA) for a group of leading anesthesiologists and key opinion leaders in the field. <br /> Professor Ralf E. Gebhard, M.D., from the University of Miami, discussed the CompuFlo® technology and its areas of clinical application.<br /> Dr. Gephard also addressed the COMPASS clinical study, a randomized, controlled, parallel group, multicenter, pivotal study aimed at assessing the safety and effectiveness of epidural space verification with the CompuFlo® Epidural Computer Controlled System. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo® technology in identifying and confirming the epidural space location as part of the US regulatory pathway. Dr. Gephard shared the initial outcome of patient data in procedures where an epidural was required for chronic pain management. Study results suggested that the non-invasive CompuFlo® technology was as accurate and effective as the current standard of medical care – the loss of resistance technique assisted with radiological X-ray based fluoroscopy – in objectively and accurately identifying the epidural space. Dr. Gephard emphasized that data further suggested that the Compuflo® technology has the potential to successfully replace the current standard of medical care while eliminating exposure to radiation. The Board of Directors of the Issuer believes that the instrument has the potential to transform an industry that has been plagued with safety concerns with one of the highest rates of malpractice in medicine; and also believes that instrument represents the future of painless, safe and effective epidural procedures. Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market" |
| Data | Imię i Nazwisko | Stanowisko | Podpis | ||
| 2015-11-23 08:42:39 | Joseph D'Agostino | CFO |
Cena akcji Milestone
Cena akcji Milestone w momencie publikacji komunikatu to 4.0 PLN. Sprawdź ile kosztuje akcja Milestone aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Milestone.
